Immunovant, Inc. (IMVT)

27.17 -0.58 (-2.09%) 收市：04:00PM EDT

Immunovant, Inc.

320 West 37th Street
6th Floor
New York, NY 10018
United States
(917) 580-3099
https://immunovant.com

版塊: Healthcare
行業: Biotechnology
全職員工: 164

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Frank M. Torti M.B.A., M.D.	Executive Chairperson of the Board	92.5k	無	1979
Dr. Chau Cheng M.B.A., Ph.D.	Vice President of Investor Relations	無	無	無
Mr. Mark S. Levine	Chief Legal Officer & Corporate Secretary	無	無	1973
Ms. Lauren Schrier M.B.A.	Vice President of Marketing	無	無	無
Ms. Christine Blodgett	Vice President of Human Resources	無	無	無
Dr. Julia G. Butchko Ph.D.	Chief Development Officer	531k	無	1971
Mr. Andy Deig	Vice President of Financial Planning & Chief of Staff to the CEO	無	無	無
Dr. Michael Geffner M.B.A., M.D.	Chief Medical Officer	無	無	無
Ms. Julie Kirschling	Senior Vice President of Program & Alliance Management	無	無	無
Ms. Jody Roth M.S., P.M.P.	Senior Vice President of Regulatory Affairs	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

公司管治

截至 2024年4月1日 止，Immunovant, Inc. 的 ISS 管治質素評分為 10。 Pillar 分數正在審核中：7；董事會：10；股東權利：10；現金賠償：8。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。